POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Mechanism of action (MOA).
In vitro, POMALYST has been demonstrated to1:
- Inhibit the proliferation and induce apoptosis of hematopoietic tumor cells
- Inhibit the proliferation of lenalidomide-resistant multiple myeloma cell lines
- Have immunomodulatory activity. Pomalidomide enhanced T cell- and natural killer cell-mediated immunity
Based on preclinical studies:
POMALYST + dex (Pd) induces cytotoxicity in REVLIMID® (lenalidomide)*-sensitive and -resistant cells1†

- Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.
- Based on preclinical in vivo and in vitro studies, the mechanism of action statements are not meant to imply clinical outcomes.
- In combination with dex.
- In in vitro models.
See how POMALYST + dex (Pd) stimulates immune function and kills multiple myeloma cells.1
dex, dexamethasone; IL, interleukin; IMiD, immunomodulatory; NK, natural killer; NKT, natural killer T; Pd, POMALYST + dexamethasone; PI, proteasome inhibitor; TNF, tumor necrosis factor.
References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. REVLIMID [package insert]. Summit, NJ: Celgene Corp. 3. Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res. 2012;36(01):S3-S12. 4. Görgün G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116(17): 3227-3337. 5. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005;128(2):192-203. 6. Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042-4051. 7. Rychak E, Mendy D, Shi T, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016;172(6):889-901.